Full-Time

Senior Financial Analyst

Early Intervention Commercial

Posted on 8/18/2026

Deadline 8/25/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$94k - $151.8k/yr

West Chester, PA, USA + 3 more

More locations: Raritan, NJ, USA | Raynham, MA, USA | Hopewell Township, NJ, USA

Hybrid

Hybrid work is required; West Chester and Raynham are preferred, with New Jersey also considered.

Bachelor's, MBA

Category
Finance & Banking (1)
Required Skills
SAP Products
Financial analysis
Tableau
Excel/Numbers/Sheets
Financial Modeling

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A minimum of a bachelor's degree is required, preferably with a major in Finance or Accounting.
  • A minimum of three years of finance and accounting experience is required.
  • Experience with SAP, Tableau, and TM1 is preferred.
  • Excellent analytical, conceptual, communication, and interpersonal skills are required, including proficiency with Microsoft Excel.
  • Collaborative skills to work effectively in a matrix organization across functional groups are required.
  • The ability to think creatively and work in a team environment is required.
  • The candidate must work well in a dynamic environment, work independently, handle multiple tasks simultaneously, and recommend and implement process improvements.
  • The candidate must be able to effectively communicate and influence others at all levels within a matrixed organization.
  • Strong accounting and analytical skills, accuracy with attention to detail, the ability to work under minimal supervision, prioritization and organization skills, planning aptitude, the ability to frame and communicate complex data, continuous operational improvement experience, and the ability to build effective partnering relationships are required.
  • English proficiency is required.
Responsibilities
  • Partner with Early Intervention leadership and cross-functional teams to build financial models and forecasts for revenue, standard cost of goods sold, and operating expenses.
  • Own the Early Intervention profit and loss statement by performing month-end close responsibilities, including preparing journal entries and accruals, commenting on actual versus forecasted results, reporting headcount, and presenting results to financial leadership.
  • Complete Early Intervention profit and loss Latest Thinking analysis monthly.
  • Influence business pricing performance through advanced analytics and support new Managed Care Organization access bids.
  • Work with the Johnson & Johnson Innovative Medicine Government Pricing team to ensure quarterly pricing calculations are accurate and reported correctly.
  • Complete ad hoc analysis for business and finance partners covering price, gross to net, gross profit, and sales and marketing operating expenses.
  • Participate actively in Early Intervention Quarterly Business Reviews and present financial results to the cross-functional leadership team.
  • Support the Strategic Deal Desk by modeling opportunities to ensure proposed deals and offerings are financially beneficial to DePuy Synthes and the customer.
Desired Qualifications
  • An MBA, Certified Public Accountant, Certified Management Accountant, and/or other financial certifications are preferred.
  • Experience with SAP, Tableau, and TM1 is preferred.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
  • TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
  • The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.

What critics are saying

  • Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
  • The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
  • A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.

What makes Johnson & Johnson unique

  • J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
  • TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
  • TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.

Psychedelic Alpha
Aug 18th, 2026
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.